Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study concluded that in female pattern hair loss patients, CGF and i-PRF treatments were more effective than PRP in increasing target area hair count, with i-PRF having the lowest adverse event rate.

This study investigated the effectiveness of combining microneedling with 2% topical minoxidil in women with mild-to-moderate androgenetic alopecia and found that adding microneedling every 2 or 4 weeks did not enhance outcomes compared to using minoxidil alone over 24 weeks.

In this multicenter Phase II trial, researchers found that topical GT20029 significantly increased hair regrowth in Chinese adult males with androgenetic alopecia compared to placebo, demonstrating good tolerability and suggesting the need for further studies to confirm its therapeutic potential.

This Phase II trial found that topical GT20029 significantly increased hair count and width at 12 weeks in Chinese men with androgenetic alopecia compared to placebo, with good tolerability and similar adverse event incidence across groups.

Among men with androgenetic alopecia, this study found that taking 5 mg of KX-826 twice daily significantly increased hair count compared to a placebo, with the treatment being well-tolerated and no serious adverse effects reported.

This study found that the new minoxidil formulation, DC0120, was noninferior to the marketed product ALOSTIL® in promoting hair growth for men with androgenetic alopecia over 16 weeks.

In this study, the researchers found that the topical generic 5% new minoxidil foam is as effective and safe as the 5% Rogaine® foam in increasing hair density and diameter in men with androgenetic alopecia over 24 weeks.

This randomized controlled trial investigated the impact of a placebo on non-vellus hair count in individuals with androgenetic alopecia, a common form of hair loss affecting both men and women, but results were not reported.

In this study, topical finasteride 0.25% showed sustained effectiveness over 52 weeks, especially in the frontotemporal areas of men with androgenetic alopecia, while maintaining an excellent safety profile.

In this study, ultraviolet light did not significantly enhance or worsen hair growth induced by topical minoxidil in men with male pattern baldness.

This randomized trial found that topical GT20029 significantly increased hair counts and width in Chinese men with androgenetic alopecia over 12 weeks, showing better results than placebo, with the 0.5% once daily and 1.0% twice weekly doses particularly effective.

This study found that clinically non-affected perilesional scalp in Japanese alopecia patients often showed microscopic abnormalities, which may help in assessing the spread of disease activities.

This study reported that two male patients with diffuse unpatterned alopecia exhibited donor-area involvement in both the vertex and occiput, challenging the assumption of occipital stability for hair transplantation, and showed partial improvement following treatment with oral finasteride and topical minoxidil.

Minoxidil effectively regrows hair in male pattern baldness.

Non-scarring hair loss can be diagnosed with two 4mm punch biopsies, one cut vertically and the other transversely.

This study found that twice-daily application of 3% topical minoxidil maintained a higher nonvellus hair count compared to once-daily application over 2 years and 9 months in men with male pattern baldness.

In this randomized study, ViviScal® significantly outperformed a fish extract in increasing non-vellus hair count and achieving clinical and histological improvement in young males with hereditary androgenic alopecia.

This analysis concluded that hair regrowth in male and female pattern hair loss treatments did not involve converting vellus hairs into terminal hairs, suggesting a reactivation of dormant non-vellus follicles instead.

In this randomized controlled trial, researchers are assessing the efficacy and safety of acupoint catgut embedding combined with topical 5% minoxidil in treating androgenetic alopecia among 70 men, with primary outcomes focusing on changes in hair count after 24 weeks of treatment.

This phase II study found that a 0.05% topical dutasteride solution was more effective than oral finasteride (1 mg/day) in increasing hair count and width in males with androgenetic alopecia over 24 weeks, without causing irritation.

This review examines the efficacy and safety of using minoxidil at concentrations greater than 5% for androgenetic alopecia but reports no new clinical results, emphasizing a need for further research.

Minoxidil treatment increased hair growth for up to 5 years, requiring twice daily application.

This article reviews the potential of topical minoxidil to cosmetically thicken hair in some individuals with male pattern hair loss, but it reports no new clinical results.

In this 48-week trial, 5% topical minoxidil was more effective than both 2% minoxidil and placebo in promoting hair growth in women with female pattern hair loss, with notable improvements in nonvellus hair count and hair growth assessments.

This study found that 2 percent topical minoxidil significantly increased nonvellus hair count and showed moderate regrowth compared to placebo in women with mild to moderate androgenetic alopecia, although participants did not notice the difference.

This study found that minoxidil 2% increased nonvellus hair counts in women with female androgenetic alopecia without causing serious side effects, compared to a placebo.

In this study, AMP-303 injections demonstrated a trend toward increasing non-vellus hair count in men with mild to moderate androgenetic alopecia, notably showing a 14.5% peak increase at 60 days compared to saline, with effects lasting up to five months.

This study reports that quantitative trichoscopy, while noninvasive and convenient, provides less accurate hair density data compared to invasive histopathologic examination, which was demonstrated in a sample of adult Chinese individuals without alopecia.

The document concludes that understanding nail anatomy is key for diagnosing nail diseases, early signs of nail melanoma may allow for less aggressive treatment, and specific genetic mutations are important in thyroid cancer prognosis and treatment.

This chapter reviews trichoscopic criteria and diagnostic features for various hair and scalp conditions, emphasizing their utility in non-invasive diagnosis, but reports no new clinical results.